Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

2026-04-08 | original

read original get Mitochondrial DNA Repair Kit → more articles

Why This Matters

This correction clarifies sample labeling in a key figure of the study on pancreatic cancer cells, ensuring scientific accuracy and integrity. Although the correction does not impact the study's conclusions, it highlights the importance of precise data presentation in research. Such transparency maintains trust in scientific findings, which is crucial for ongoing advancements in cancer research and targeted therapies.

Key Takeaways

Accurate sample labeling is vital for data integrity in scientific publications.
Corrections, even minor, help maintain transparency and trust in research findings.
The study's main conclusions about mitochondrial function in pancreatic cancer remain unaffected.

Since the version of the article initially published, a sample mislabeling issue has been brought to the authors’ attention concerning the immunoblots shown in Figs. 4a and 2b. The samples in Fig. 4a should have been labeled as “No. 3” and “No. 4”, rather than “No. 1” and “No. 2” as originally indicated. An updated version of Fig. 4a with the corrected sample identifiers is shown below as Fig. 1. This mislabeling issue does not alter the text or conclusions of the article. This notice serves to amend the error.

Fig. 1: Corrected Fig. 4a. Full size image a, Immunoblot of Thr-172-phosphorylated and total AMPK, Ser-79-phospho-acetyl-coA-carboxylase (pACC) and β-actin in +/−KRas cells from two independent tumours.

Explore topics: oncogene pancreatic cancer mitochondrial function immunoblot kras